Figure S2 from Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia

Autoría

autor: James S Fraser, Shahein Tajmir, Brenton G Mar, Alison M Schram, Patrick Walters, Adam Frost, D Randal Kipp, Yakov Pechersky, Erika G Puente, Andreas Varkaris, Ramin Samadani, Michael J Holliday, Fabrizio Giordanetto, Jonathan R LaRochelle, Erika Hamilton, David E. Shaw